Virus Research,
Год журнала:
2024,
Номер
351, С. 199507 - 199507
Опубликована: Дек. 13, 2024
Chronic
hepatitis
B
(CHB)
is
a
significant
global
health
issue
affecting
approximately
254
million
individuals
worldwide.
Achieving
the
loss
of
surface
antigen
(HBsAg),
either
with
or
without
seroconversion
to
antibody
(HBsAb),
regarded
as
functional
cure
and
optimal
goal
for
addressing
CHB,
can
be
achieved
through
various
approaches,
including
induction
nucleos(t)ide
analogues
(NAs),
pegylated
interferon
alpha
(PegIFNα),
spontaneous
clearance
HBsAg.
Spontaneous
HBsAg
rare,
while
NAs
directly
inhibit
HBV
DNA,
they
are
unable
act
on
covalently
closed
circular
DNA
(cccDNA),
hence
inhibiting
production
clearing
extremely
challenging.
On
other
hand,
based
PegIFNα
shows
good
long-term
durability,
but
over
10
%
patients
still
experience
relapse,
mostly
within
48
weeks
after
cure.
Factors
related
CHB
antiviral
therapy
complex,
host
factors,
viral
environmental
etc.
The
integration
into
liver
cells,
persistence
cccDNA,
insufficient
cell
responses
compromised
T
function
pose
barriers
clearance.
Therefore,
this
study
systematically
reviewed
relevant
factors
potential
mechanisms
influencing
which
provide
basis
personalized
treatment,
help
predict
treatment
outcomes
assess
prognosis,
theoretical
support
advancement
novel
strategies
medications.
World Journal of Hepatology,
Год журнала:
2025,
Номер
17(1)
Опубликована: Янв. 6, 2025
Due
to
sedentary
lifestyle
and
rising
prevalence
of
obesity,
patients
with
general
population
those
who
are
infected
chronic
hepatitis
B
found
have
metabolic
dysfunction
associated
steatotic
liver
disease
(MASLD).
Both
virus
(HBV)
infection
MASLD
can
damage
hepatocytes
in
their
own
way,
but
concomitant
HBV-MASLD
has
its
clinical
implications.
Cherry
on
top
is
the
presence
diabetes
mellitus,
hypertension
or
obesity
which
added
more
chances
unfavorable
outcomes
these
patients.
In
this
article,
we
comment
article
by
Wang
et
al
published
recent
issue.
This
provides
a
comprehensive
overview
complex
interaction
between
HBV-MASLD,
HBV
alone
We
discuss
key
findings
from
studies,
including
promising
observed
concurrent
MASLD,
warrants
further
research.
The
insights
presented
here
offer
renewed
understanding
interaction.
The American Journal of Gastroenterology,
Год журнала:
2024,
Номер
unknown
Опубликована: Июнь 26, 2024
INTRODUCTION:
The
prevalence
of
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
increasing
among
the
chronic
hepatitis
B
(CHB)
population.
This
study
aimed
to
explore
impact
dysfunction
(MD)
on
cirrhosis
and
cirrhotic
complication
risks
in
CHB.
METHODS:
Patients
with
CHB
were
consecutively
recruited
between
2006
2021.
presence
MD
was
based
5
cardiometabolic
criteria
specified
MASLD
definition.
categorized
into
MD/non-MD
groups
these
criteria.
RESULTS:
Eleven
thousand
five
hundred
two
treatment-naive
noncirrhotic
patients
included
a
median
follow-up
5.3
years.
group
(n
=
7,314)
older
had
lower
virus
DNA
levels
than
non-MD
4,188).
After
adjustment
for
clinical
viral
factors,
significantly
higher
(adjusted
hazard
ratio
[aHR]:
1.82,
95%
confidence
interval
[CI]:
1.40–2.37,
P
<
0.001)
complications
(aHR:
1.30
per
MD,
CI:
1.03–1.63,
0.025)
dose-dependent
manner.
Furthermore,
new-onset
diabetes
mellitus
during
aggravated
risk
2.87,
1.34–6.11,
0.006).
Hepatic
steatosis
associated
0.57
within
years,
0.44–0.74,
0.45,
CI
0.23–0.88,
0.020).
Among
individuals
hepatic
steatosis,
exhibited
patients.
DISCUSSION:
Concurrent
MDs
increase
CHB,
independent
steatosis.
Proactively
investigating
comorbidities
critical
stratify
progression.
International Journal of General Medicine,
Год журнала:
2025,
Номер
Volume 18, С. 1591 - 1604
Опубликована: Март 1, 2025
To
evaluate
liver
complications
in
patients
with
chronic
hepatitis
B,
both
and
without
cardiometabolic
comorbidities,
to
compare
the
incidence
of
comorbidities
these
that
general
population.
This
nationwide
registry-based
cohort
study
included
data
from
2002-2020.
In
primary
analysis,
we
used
multivariate
Poisson
regression
estimate
rate
ratio
stratified
by
presence
comorbidities.
secondary
compared
developing
B
those
Both
analyses
were
adjusted
for
sex,
age,
country
origin,
while
analysis
was
additionally
time
since
comorbidity
diagnosis
calendar
year.
The
4731
whom
532
(11%)
had
at
least
one
comorbidity.
unadjusted
overall
1.0
per
100
person-years
(95%
confidence
intervals:
0.84-1.30)
0.4
0.30-0.42)
without.
highest
first
year
following
population,
1.10
1.02-1.19).
Sensitivity
revealed
a
higher
type
2
diabetes
hypertension
but
lower
hypercholesterolemia.
Patients
exhibit
complications,
particularly
Furthermore,
have
than
Clinical and Molecular Hepatology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 6, 2025
Background/Aims:There
are
no
hepatocellular
carcinoma
(HCC)
surveillance
recommendations
for
non-viral
chronic
liver
diseases
(CLD),
such
as
metabolic
dysfunction
associated
steatotic
disease
(MASLD).We
explored
the
Steatosis-Associated
Fibrosis
Estimator
(SAFE)
score
to
predict
HCC
in
MASLD
and
other
CLD
etiologies.
Methods:Patients
with
various
CLDs
were
included
from
medical
centers
Taiwan.The
SAFE
score,
consisting
of
age,
BMI,
diabetes,
laboratory
data,
was
calculated
at
baseline,
patients
traced
new
development
HCC.The
predictability
analyzed
using
subdistribution
hazard
model
adjustments
competing
risks.
Results:Among
12,963
a
median
follow-up
4
years,
258
developed
classifies
1,
3,
5-year
risk
regardless
etiologies.High
(≥100)
intermediate
(0-100)
scores
increased
11
2
folds
risks
compared
low
(<0)
scores.Combining
two
lower
tiers
(SAFE
<
100),
high
7.5-fold
(adjusted
sub-distributional
ratio
[aSHR]:
7.54,
95%
confidence
interval
(CI):
5.38-10.60).A
subgroups
viral
hepatitis,
hepatitis
(aSHR:
11.10,
95%CI:
3.97-31.30)and
4.23,
1.43-12.50).A
hospital
cohort
(n=8,103)
community
(n=120,166)
validated
prediction.
Conclusions:The
stratifies
etiologies
helps
select
at-risk
candidates
surveillance.
Clinical and Molecular Hepatology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 22, 2025
As
new
evidence
emerges,
treatment
strategies
toward
the
functional
cure
of
chronic
hepatitis
B
are
evolving.
In
2019,
a
panel
national
hepatologists
published
Consensus
Statement
on
B.
Currently,
an
international
group
has
been
assembled
to
evaluate
research
since
publication
original
consensus,
and
collaboratively
develop
updated
statements.
The
2.0
was
aimed
update
consensus
with
latest
available
studies,
provide
comprehensive
overview
current
relevant
scientific
literatures
regarding
B,
particular
focus
issues
that
not
yet
fully
clarified.
These
cover
definition
its
mechanisms
barriers,
effective
roadmap
achieve
this
endpoint,
in
surrogate
biomarkers
used
measure
efficacy
or
predict
response,
appropriate
approach
pursuing
special
populations,
development
emerging
antivirals
immunomodulators
potential
for
curing
statements
primarily
intended
offer
guidance
clinicians
their
practice
enhance
rate
